Sankyo Co., Ltd. engages in the manufacture and sale of pachinko and pachislot machines. It operates through the following segments: Pachinko Machines Business, Pachislot Machines Business, Ball Bearing Supply Systems Business, and Others. The Pachinko Machines Business segment produces and sells pachinko machines, machine gauges and its related parts. The Pachislot Machines Business segment markets pachislot machines and related parts. The Ball Bearing Supply Systems segment sells pachinko and pachislot ball feeders, card system equipment, and parlor-related equipment. The Others segment comprises of mobile content service, real estate, golf club operations, and sells general molding products. The company was established on April 12, 1966 and is headquartered in Tokyo, Japan.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Develops anticancer therapies from soil-dwelling micro organisms

The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Kalamazoo, Michigan, by Dr. William E. Upjohn, an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. These could be "reduced to a powder under the thumb", a strong marketing argument at the time.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Hayao Cihang Pharmaceutical Co. Ltd. is a private company headquartered in China that manufactures and distributes pharmaceutical products.

Changsha Cihang Pharmaceutical Research Institute is a company headquartered in Changsha, China and ultimately controlled by the Government of China, that engages in pharmaceutical research; manufactures medicine.

Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Changsha Tianci Biomedical Technology Co., Ltd., established on 2005-08-24, Business scope includes natural science research and experimental development;Engineering and Technology Research and Experimental Development;Research and development of biological products;Research and development of plant extracts;Medical Research and Experimental Development;drug development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Sanko is a manufacturer and seller of press products, mechatronics products, and plastic products. Their product and technology categories include press products, plastic products, and mechanism development design proposals. Their equipment lists such as press product mass production equipment, mass production equipment for plastic products, and mold manufacturing equipment.

Zhejiang Huanda Biotechnology Co., Ltd., established on 2020-01-08, Business scope includes general items:Biochemical product technology research and development;Chemical product production(No licensed chemical products);Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products);Food Additive Sales;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Healthy food(prepackaged)Sales;R&D of industrial enzyme preparations;Fermentation process optimization technology research and development;Research and development of bio-based materials technology;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Extraction of marine bioactive substances,purification,Synthesis technology research and development;Import and export;Technology Import and Export;Import and export agency(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;Drug import and export;Feed additive production;Veterinary drug production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Meiji Seika Pharma Co., Ltd. engages in the business of manufacture and distribution of pharmaceutical products. It also engages in the animal health business. The company was founded on October 9, 1916 and is headquartered in Tokyo, Japan.